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Synaptic loss is an early pathological finding in Alzheimer’s disease (AD) and correlates 
with memory impairment. Changes in macroscopic brain activity measured with electr o- 
and magnetoencephalography (EEG and MEG) in AD indicate synaptic changes and may 
therefore serve as markers of intervention effects in clinical trials. EEG peak frequency 
and functional networks have shown, in addition to improved memory performance, 
to be sensitive to detect an intervention effect in mild AD patients of the medical food 
Souvenaid containing the specific nutrient combination Fortasyn® Connect, which is 
designed to enhance synapse formation and function. Here, we explore the value of 
MEG, with higher spatial resolution than EEG, in identifying intervention effects of the 
nutrient combination by comparing MEG spectral measures, functional connectivity, 
and networks between an intervention and a control group. Quantitative markers 
describing spectral properties, functional connectivity, and graph theoretical aspects of 
MEG from the exploratory 24-week, double-blind, randomized, controlled Souvenir II 
MEG sub-study (NTR1975, http://www.trialregister.nl) in drug naïve patients with mild 
AD were compared between a test group (n = 27), receiving Souvenaid, and a control 
group (n = 28), receiving an isocaloric control product. The groups were unbalanced at 
screening with respect to Mini-Mental State Examination. Peak frequencies of MEG were 
compared with EEG peak frequencies, recorded in the same patients at similar time 
points, were compared with respect to sensitivity to intervention effects. No consistent 
statistically significant intervention effects were detected. In addition, we found no differ-
ence in sensitivity between MEG and EEG peak frequency. This exploratory study could 
not unequivocally establish the value of MEG in detecting interventional effects on brain 
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activity, possibly due to small sample size and unbalanced study groups. We found no 
indication that the difference could be attributed to a lack of sensitivity of MEG compared 
with EEG. MEG in randomized controlled trials is feasible but its value to disclose inter-
vention effects of Souvenaid in mild AD patients needs to be studied further.
Keywords: magnetoencephalography, brain networks, clinical trial, alzheimer’s disease, medical nutrition
inTrODUcTiOn
Alzheimer’s disease (AD) is the leading cause of dementia, and 
although it has an incompletely understood etiology, synaptic 
connectivity seems to be reduced already in early stages (1, 2). 
Synapses are the main structures for functional connectivity 
between neurons, and loss of this connectivity is related to 
impaired cognition in AD (3). Therefore, optimizing synapse 
formation and function may counteract some of the cognitive 
effects of the AD process.
Synapses consist of a large part of neuronal membrane, and 
formation and function of neuronal membrane can be enhanced 
by increasing the availability of specific nutrients that are required 
for the synthesis of phospholipids [for an overview, see Ref. (4)]. 
In many in vitro and in vivo studies, the combined administra-
tion of these nutrients has been shown to increase brain levels 
of phospholipids and synaptic proteins, to increase synaptic 
density, to enhance cholinergic neurotransmission and receptor 
functioning, and to improve functional brain connectivity and 
cognitive performance [e.g., Ref. (5–11)].
The medical food Souvenaid contains the specific nutrient 
combination Fortasyn Connect which was designed to counteract 
synapse loss and dysfunction in AD by supplying precursors and 
cofactors that are essential for neuronal membrane formation 
and maintenance and that are believed to be insufficiently avail-
able in AD, i.e., docosahexaenoic acid (DHA), eicosapentaenoic 
acid (EPA), uridine (in the form of uridine monophosphate), 
choline, phospholipids, folic acid, vitamins B6, B12, C, E, and 
selenium.
Souvenaid is intended as a medical food for oral consump-
tion under medical supervision with the purpose of addressing 
disease-specific nutrient requirements. It has been found to 
positively affect memory function in mild AD (12–14).
Neurophysiological measures aid in the interpretation of 
the mode of action of an intervention (15). A previous clinical 
study showed preserved EEG spectral and graph theory-based 
functional network measures in patients receiving Souvenaid 
compared with a control group in a double-blind, randomized, 
controlled trial, indicating preserved connectivity as a macro-
scopically measurable objective intervention effect (14). Recent 
research suggests that the AD effect is not homogeneously dis-
tributed over different brain regions and that, in terms of brain 
networks, especially highly connected hub regions are affected 
(16–18). More spatially detailed information in these hub areas 
could therefore potentially disclose additional information on the 
mode of action of the intervention. Magnetoencephalography 
(MEG) combines a high temporal resolution with a relatively 
high spatial resolution. MEG signals are hardly disturbed by 
the skull, and absolute values can be used without the need for a 
reference. This allows the study of brain activity in great spatial 
detail and a reliable transformation to anatomical space.
Magnetoencephalography recordings in AD patients have 
mainly shown loss of functional connectivity of fast (>8  Hz) 
oscillatory brain activity and a less optimal network structure 
(18–22). However, no intervention studies have been performed 
in AD patients to improve the abnormalities seen with MEG 
recordings. We therefore set out to examine in an exploratory 
setting the feasibility and value of MEG to detect intervention 
effects of a medical food on brain activity in mild AD patients.
MaTerials anD MeThODs
study Design and subjects
Fifty-five patients aged ≥50  years, meeting the criteria for 
AD according to the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s 
Disease and Related Disorders Association (NINCDS-ADRDA) 
criteria and with a Mini-Mental State Examination (MMSE) 
≥20 were enrolled in the Souvenir II MEG sub-study, which 
had an exploratory, randomized, controlled, double-blind, 
parallel-group design. Participants were 1:1 randomly allocated 
to either the test (Souvenaid, containing Fortasyn Connect) or 
the isocaloric control product (without Fortasyn Connect) as a 
125-ml daily drink for 24 weeks based on a computer-generated 
randomization list. Patient inclusion and exclusion criteria were 
identical to those previously described in the Souvenir II study 
(14). Assessments were done at baseline, week 12, and week 24, 
including MEG, EEG, blood sampling, safety, and compliance 
based on diaries. Participants were recruited from one center in 
Amsterdam (n = 47), one center in Madrid (n = 2), and one center 
in Barcelona (n =  6). The study was conducted in accordance 
with the Declaration of Helsinki, the International Conference 
on Harmonization (ICH) guidelines for Good Clinical Practice 
(GCP) as appropriate for nutritional products, and local legisla-
tion of the country in which the research was conducted. The 
Dutch Trial Registration number for this study is NTR1975. 
The ethical review boards of the local study sites approved the 
study. Written informed consent was obtained from patients and 
caregivers.
Meg recording and Post-Processing
Figure 1 shows an overview of the MEG recording and analysis 
steps. Twenty-minute eyes-closed resting-state MEG data were 
recorded using whole head MEG systems inside a magnetically 
shielded room in three centers (Table  1). The head position 
within the scanner was determined by using four attached head 
position indicator coils. The positions of the indicator coils and 
FigUre 1 | Meg recording and analysis pipeline. Arrows indicate steps in time. Source-space MEG of the patient was reconstructed using the signal-space 
MEG time series, the patient’s MRI, and an anatomical atlas (input data). MEG was used for frequency analysis (with outcome parameters: peak frequency and 
relative power) and the construction of a functional connectivity-based (PLI) adjacency matrix. From this matrix, mean PLI as well as weighted network measures 
gamma and lambda were computed and the minimum spanning tree (MST) matrix was derived. From the MST matrix, network metrics betweenness centrality, 
eccentricity, leaf fraction, diameter, and tree hierarchy were computed. All outcome measures were compared between groups.
TaBle 1 | Descriptive data of the recording Meg laboratories.
Department of clinical neurophysiology,  
Meg center, VU Medical center
laboratory of cognitive and computational 
neuroscience (UcM-UPM), center for  
Biomedical Technology
Magnetoencephalography 
Unit, centro Medico  
Teknon
City, country Amsterdam, the Netherlands Madrid, Spain Barcelona, Spain
MEG system Elekta Elekta 4D Neuroimaging
Number of subjects 47 2 6
Sensor types 102 magnetometers and 204 planar gradiometers 102 magnetometers and 204 planar gradiometers 146 magnetometers
Sampling rate (Hz) 1250 1000 678
Online filtering (pass band, Hz) 0.1–410 0.03–330 1–70
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the head shape were determined before the recordings using a 
digitizer (3Space Fast-Track, Polhemus, Colchester, VT, USA). 
The recorded MEG data were transferred to the Amsterdam 
center for central post-processing. Channels with poor signal 
quality (maximum of 10) were manually de-selected after visual 
inspection for artifacts by a trained technician, and addition-
ally a spatio-temporal Signal-Space Separation (tSSS) filter 
(Elekta data) was applied for artifact removal (10  s window, 
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activity–noise correlation set at 0.9) using MaxFilter software 
(Elekta-Neuromag Oy version 2.2.10) (23). Head movement and 
number of discarded channels did not differ between recording 
centers.
A beamformer method was used to transfer the signal-space 
data of the Elekta MEGs (n = 49 subjects) to source-space for 
further analysis: the MEG signals, recorded at the sensors, were 
reconstructed to MEG signals originating from 78 sources 
[according to the 78 automated anatomical labeling (AAL) 
areas] (24–26). Therefore, magnetic resonance imaging (MRI) 
T1 series of the patients were coregistered on the MEG data 
using the current head position and digitized scalp, as well as 
the outline of the scalp as obtained from the MRI outline data. 
For nine subjects, no suitable MRI was available. For these 
subjects, the best fitting MRI was identified out of the MRIs 
available from this study and used for matching with satisfying 
matching results. The MEGs recorded using 4D Neuroimaging 
(Barcelona, n  =  6) were analyzed separately in the original 
signal-space, due to incompatible software requirements for 
source-space computation. Five artifact-free epochs of 4096 
samples (down-sampled four times, 13.1–16.4 s) were selected 
from each recording by a trained MEG technician and analyzed 
with in-house developed open access software (BrainWave, 
version 0.9.72, C. J. Stam, http://home.kpn.nl/stam7883/brain-
wave.html).
For the source-space MEGs, outcome measures included 
measures for analysis A (characterized by one average value 
per subject per time point, see Statistical Analysis) and meas-
ures for analysis B (with one value for each AAL region per 
MEG study, see Statistical Analysis). The measures for analysis 
A included mean occipital peak frequency (for comparison 
with the previous Souvenir II EEG study and defined as the 
median frequency between 4 and 13 Hz, averaged across the 
signals of the occipital regions), relative power in the different 
frequency bands (averaged over all brain regions), functional 
connectivity [assessed with the Phase Lag Index (PLI) and aver-
aged over all brain regions], and several functional network 
measures [mean normalized clustering coefficient (gamma), 
the averaged normalized shortest path length (lambda), and 
minimum spanning tree (MST) network-derived measures 
(leaf fraction, diameter, tree hierarchy, maximum between-
ness centrality, and maximum eccentricity)]. The measures 
for analysis B included non-averaged region-specific peak 
frequency, relative power, functional connectivity, and MST 
betweenness centrality and eccentricity (27–30). Analyses 
were performed in six frequency bands (delta 0.5–4 Hz, theta 
4–8  Hz, alpha1 8–10  Hz, alpha2 10–13  Hz, beta 13–30  Hz, 
and gamma 30–48 Hz). Functional connectivity quantifies the 
functional interactions between brain regions with high values 
indicating a strong functional connection and low values indi-
cating a weak or absent functional connection. The MSTs were 
constructed in such a way that all network nodes were included 
in the graph using the connections with the highest functional 
connectivity and without the formation of loops (29). Only 
descriptive statistics with respect to relative power and peak 
frequency were analyzed for the signal-space MEG subsample 
(Barcelona).
Post Hoc analysis
In addition to MEG, the participants underwent 20-min eyes-
closed task-free EEG according to the protocol used in the previ-
ous Souvenaid II study just before or after the MEG measurement 
(14). In short, digital EEG was recorded according to the 10–20 
system with 21 electrodes and sample frequency 500 Hz (BrainRT, 
OSG Belgium). To compare source-space MEG’s sensitivity in 
detecting an intervention effect to that of EEG, we additionally 
analyzed peak frequency based on sensor-level EEG data from 
the same study sample (n = 49) using a common or average refer-
ence, online filter settings high pass 0.16 Hz and low pass 70 Hz. 
As for MEG, EEG peak frequency was computed for the parieto-
occipital electrodes (P3, P4, O1, and O2) as the median frequency 
between 4 and 13 Hz. Only peak frequency was assessed since this 
parameter had the most clearly interpretable significant results in 
the previous Souvenir II EEG study and is (contrary to functional 
connectivity and network measures) not dependent on number 
of electrodes/sensors.
safety and compliance
Safety assessments included the examination of patient medical 
history, recording of (serious) adverse events [(S)AE], and the 
monitoring of vital signs and additional laboratory parameters 
(liver panel and renal function). Study product compliance was 
assessed using a daily diary, which was completed by the subject 
or caregiver at home.
Magnetoencephalography analyses were done on the 
intent-to-treat (ITT) MEG population (n =  49), defined as all 
 randomized patients (ITT) with source-space reconstructed 
MEGs. Safety analyses were performed on the all-subjects treated 
(AST) population (n = 55), defined as all randomized patients 
who received at least one dose of study product.
statistical analysis
No previous study results were available on intervention in AD 
patients to improve abnormalities seen with MEG recordings on 
which the sample size calculation could be based. With the pro-
posed sample size of 20 patients per group, a treatment difference 
of about 1 SD can be detected with a power of 90% using t-test 
and a two-tailed alpha of 0.05.
Source-space MEG outcome parameters that yield one value 
per subject per time point (Analysis A: mean occipital peak 
frequency, mean PLI, gamma, lambda, leaf fraction, diameter, 
tree hierarchy, maximum betweenness centrality, and maximum 
eccentricity) were analyzed using mixed models for repeated 
measures (MMRM) with change-from-baseline as an outcome, 
using SAS® software (SAS Enterprise Guide 4.3 for Windows, 
SAS Institute Inc., Cary, NC, USA) and in line with the previous 
Souvenir II EEG sub-study. More specifically, a mixed model by 
specifying the within subject unstructured variance– covariance 
structure and including group (treatment arm), time (as continu-
ous variable; treatment duration), and the group × time interac-
tion as fixed effects, adjusted for baseline values (baseline was 
included as covariate) was used. “Site” was not included as random 
effect, because MEG data for the primary MEG analysis (based 
on “source-space”) were only available from two sites and the 
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majority of the data were collected at one single site. Normality of 
the distribution was checked, and no transformations to correct 
for lack of normality were needed. The two degrees of freedom 
contrast (for group and group × time) describing the difference 
in trajectories over time between Souvenaid and control groups 
was taken as the primary indication of treatment effect during the 
intervention period.
Source-space MEG outcome parameters that yield one value 
per AAL region per subject per time point (analysis B: peak 
frequency, relative power, PLI, MST betweenness centrality, and 
MST eccentricity) were analyzed with two different approaches: 
(1) to adhere to the analysis method of the previous Souvenir II 
EEG sub-study and to take into account covariates and evolution 
over time, a statistical analysis with average values for 10 prede-
fined brain areas [consisting of 2 (left and right) times 5 (frontal, 
central, temporal, parietal, and occipital) regions] to examine 
whether an interaction of treatment and time was constant over 
the 10 brain areas with brain area as additional fixed factor and 
(2) to use the higher spatial resolution of the MEG, a permutation 
analysis with each of the 78 AAL regions, correcting for multiple 
comparisons to indicate the brain regions responsible for group 
differences. With this method, we derived a null distribution for 
between-group differences by permuting group assignment and 
calculating a t-statistic after each permutation with an independ-
ent t-test (31). The maximum t-value across ROIs of each permu-
tation was used to construct a distribution of maximum t-values 
of 1000 permutations. To correct for multiple comparisons, we 
used the single threshold test with p-value set at 0.05.
resUlTs
subject Flow
Figure 2 and Table 2 show the flow and demographic data of sub-
jects throughout the study for both study groups, separately for 
the total ITT population and the ITT MEG analysis population. 
Five subjects (9%) withdrew from the study early (n = 2 subjects 
from the test group and n = 3 subjects from the control group). 
Reasons for early withdrawal were withdrawal of consent (n = 2, 
1 in each group), occurrence of SAEs (n = 2, 1 in each group), 
and lost to follow-up (n = 1 in the control group). Subjects were 
well balanced over the study groups with respect to baseline 
characteristics, except for the total MMSE score. Despite the 
randomization procedure, mean total MMSE score at screening 
was significantly higher for the control group compared with the 
test group in both ITT populations (total ITT population: t-test, 
p = 0.021; ITT MEG analysis population: t-test, p = 0.032), indi-
cating worse cognition at screening in the test group as compared 
with the control group.
Meg results
Peak frequency and relative power of the source-space data were 
not different between the groups over the 24-week intervention 
period with any of the statistical methods (Appendices A and 
B in Supplementary Material). Mean functional connectivity as 
measured with PLI was not different between groups (MMRM, 
Appendix C in Supplementary Material), but with regional analy-
sis using permutation testing, the test group showed significant 
lower theta band values in the left gyrus rectus (permutation test; 
p <  0.05). The network measures were generally not different 
between the groups except that the MMRM showed a group dif-
ference over time for normalized clustering coefficient gamma in 
the alpha-2 band [MMRM; F(2,43) = 3.91, p = 0.028] and tree 
hierarchy in the theta band [MMRM; F(2,43) = 5.38, p = 0.008], 
but at endpoint no differences were observed between study 
groups (Figure 3; Appendices D–J in Supplementary Material). 
In addition, the permutation analysis showed a significantly 
lower theta band MST betweenness centrality at baseline in the 
left gyrus rectus in the test group compared with the control 
group (permutation test; p < 0.05). Descriptive statistics for mean 
peak frequency and relative power of the MEGs in signal-space 
(from Barcelona, n = 6) are presented in Appendices K and L in 
Supplementary Material.
Post Hoc results
In agreement with the MEG results, EEG peak frequency analysis 
yielded no group differences, suggesting that MEG is not neces-
sarily less sensitive than EEG to detect an intervention effect.
Post hoc analyses were conducted to test the influence of gender 
on the intervention effect on the MEG outcome parameters. We 
could not demonstrate an intervention effect in males or females 
when tested separately.
As significant differences were observed in screening MMSE 
between the study groups, additional statistical analyses were 
conducted for all MEG parameters adjusting for screening 
MMSE. The results from these confounder analyses were similar 
to the results from the primary MEG analyses, indicating no 
straightforward confounding effects of screening MMSE.
safety and compliance
Regarding safety, no clinically relevant differences between 
groups were found for the blood safety parameters, (S)AE occur-
rence, and vital signs assessments. The calculated subject reported 
compliance during 24 weeks was high with 91% in the test group 
and 98% in the control group (Student’s t-test, p = 0.19).
DiscUssiOn
summary
This Souvenir II MEG sub-study was a 24-week study in 55 patients 
with mild AD to explore whether MEG has the potential to detect 
effects resulting from 24 weeks’ intake of Souvenaid compared 
with a control product. Based on results from a previous EEG 
study, we expected group differences in the peak frequency, delta 
band functional connectivity, and beta band network parameters 
gamma and lambda (14, 32). However, we observed no endpoint 
differences in the MEG measures between the test group and the 
control group. Although some differences in trajectory over time 
were found (gamma in the alpha2 band and MST tree hierarchy 
in the theta band), these findings were not confirmed by differ-
ences at endpoint and did not reveal a consistent pattern that was 
anticipated based on the previous EEG results, existing knowl-
edge on AD pathology, and the hypothesized mode of action of 
Souvenaid. Due to the number of tests, we anticipate that these 
results may have resulted from type 1 errors. The study product 
FigUre 2 | subject flow chart. *MEG analysis population, excluding six subjects from Barcelona.
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was safe and well tolerated, as has been shown previously in mild 
and in mild-to-moderate AD (13, 14).
relationship between souvenaid, 
synapses, and electrophysiological 
changes in aD
The main mechanism for neuronal communication is synaptic 
transmission of electrical current. Synapses as specialized parts of 
the cell membrane are built to facilitate transmission of current by 
continuous excitatory and inhibitory input from sending axons 
to receiving dendrites. As a result, postsynaptic potentials are 
constantly changing, and the net fluctuation of the electrical field 
can be measured as oscillations of the magnetic field with MEG 
and of the electrical field with EEG. The most consistent electro-
physiological finding in AD is slowing of the oscillatory activity 
(33). The exact mechanism of this phenomenon is unknown, but 
model studies indicate that loss of synaptic connectivity plays a 
FigUre 3 | Mean normalized clustering coefficient (gamma) in the alpha 2 band (a) and minimum spanning tree hierarchy in the theta band (B) at 
baseline, week 12, and week 24. Data are raw means ± SEM.
TaBle 2 | Baseline demographics and characteristics of the intent-to-treat (iTT) populations.
Total iTT population iTT Meg analysis population
control  
n = 28
Test  
n = 27
control  
n = 27
Test  
n = 22
Age, years [range] 68.4 (7.9) [56–85] 69.7 (7.9) [53–87] 68.1 (7.9) [56–85] 68.4 (7.6) [53–80]
Male, n (%) 14 (50.0%) 15 (55.6%) 14 (51.9%) 12 (54.5%)
Years of education beyond primary school 6.2 (3.9) 7.6 (4.4) 6.2 (4.0) 7.2 (4.2)
Duration AD since diagnosis, months, median [range] 2.0 [0.0–46.0] 2.0 [0.0–29.0] 2.0 [0.0–46.0] 3.0 [0.0–29.0]
Total MMSE score 25.1 (2.8) 23.6 (2.1) 25.3 (2.6) 23.8 (2.3)
Data are presented as mean (SD) unless stated otherwise.
AD, Alzheimer’s disease; MMSE, Mini-Mental State Examination.
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role (18, 34). In addition, breakdown of functional network integ-
rity has also been found in EEG (35, 36) and could be modeled by 
decreasing coupling between neuronal assemblies in a computer 
model (37). The effects of the Souvenaid on brain function in early 
AD have been assessed before with EEG and preserved peak fre-
quency and network organization were related to the nutritional 
intervention (14, 32). Given the effects of the Fortasyn Connect 
nutrients on synaptic structure and function and on brain con-
nectivity in animal studies (5, 6, 10, 11) and the known changes 
on EEG in AD patients, it was hypothesized that improved 
synaptic function due to the intervention may be picked up by 
EEG as preserved oscillatory frequency and preserved functional 
network organization. In essence, MEG and EEG both measure 
the macroscopic effects of postsynaptic potential changes. It was, 
therefore, expected that the same neurophysiological principles 
and intervention effects apply to MEG.
control group results
Our control group did not behave as expected. From previ-
ous neurophysiological studies, it is clear that AD is related to 
noticeable macroscopic neurophysiological changes: the peak 
frequency and functional connectivity decrease over time, and 
network parameters indicate a more random organization of 
functional connections (15). In our control group, we could not 
observe most of these changes during the course of the study, 
indicating that our control group was not typical during the 
course of the study. On the other hand, 24 weeks may be too short 
to detect neurophysiological decline in a relative small group of 
AD subjects and therefore longer study duration may reveal the 
typical AD-related MEG changes.
Meg in relation to eeg
Although the choice of the imaging technique has a known 
influence on the results (38), we did not find indications of 
lower sensitivity of MEG compared with EEG. EEG was part of 
the study protocol, and in a post hoc analysis, we analyzed EEG 
peak frequency from the same study population at the same time 
points as the MEGs using the same software and comparable (i.e., 
occipital) cortical areas. Peak frequency is one of the most robust 
and most investigated neurophysiological measures in AD and 
behaves in a similar way in EEG and MEG with lower values in 
AD compared with controls (15, 20, 39–41). In addition, EEG 
peak frequency has previously been identified as a sensitive 
measure for group differences after 24  weeks of intervention 
8van Straaten et al. MEG in AD Clinical Trials
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with Souvenaid (14). However, in the current study, EEG peak 
frequency did not differ between the test and control groups 
over the course of the study and at endpoint. Therefore, we could 
not attribute the lack of group difference to a lower sensitivity of 
MEG compared with EEG. On the other hand, MEG, which is 
more costly, more technical demanding, and less widely avail-
able than EEG, did not perform superior to EEG in this study. 
MEG may theoretically outperform EEG given several technical 
differences: magnetic fields detected with MEG do not suffer 
from filtering effects of surrounding tissue as much as the electric 
fields detected with EEG. Therefore, the estimation of sources, 
especially when located in deeper brain structures is more reli-
able and the maximum spatial and temporal resolution is higher. 
Another potential advantage of MEG over EEG is the fact that no 
referential recording point is needed. The use of a reference has 
been shown to influence the results, especially in EEG functional 
connectivity and network studies. Despite these advantages, we 
could not establish a higher sensitivity for an intervention effect 
over 24 weeks.
limitations
Several methodological limitations can be identified. The data 
from different centers were not compatible when using the 
latest analysis techniques. The field of MEG analysis is rapidly 
developing, and the demands on the recordings and the analysis 
strategies change accordingly. At this moment, no uniform MEG 
data format is available, and recordings from different scanner 
types cannot be pre-processed similarly. Not all state-of-the-art 
techniques are available and validated for merging data from 
different MEG systems. In the current study, we decided to imple-
ment the latest analysis technique for Elekta MEGs at the cost of 
excluding several subjects from the analyses. This has led to a 
reduction of power, but we feel that the accuracy of the source-
space analysis method compensated for this loss (26). However, 
next steps toward a uniform MEG data format will likely increase 
the applicability of MEG in clinical trials.
In the current study, we did not control for time of the record-
ing. Brain oscillations as measured with EEG and MEG are 
known to vary over the course of 24  h, with the lowest power 
of the signal early in the morning (42–44). However, this diur-
nal rhythm applies to absolute oscillatory power and to a large 
extend is similar for all frequency bands. In our study, we only 
used relative frequency measures for the spectral analyses. It can, 
therefore, be expected that circadian effects will largely cancel out 
in these types of analyses, and we feel that the present results are 
not influenced substantially by differences in time of recording.
This study was exploratory in nature with small subject groups, 
which has some known drawbacks when interpreting group dif-
ferences, some of them being the larger risk of non-uniformity 
of the groups and the lack of statistical power. Unfortunately, 
the patient groups were found to be unbalanced with respect to 
screening MMSE, despite a careful computerized randomization 
process. Covariate analyses correcting for the baseline differences 
did not reveal confounding effects. However, these adjustments 
assumed a linear relationship between the baseline characteristic 
and the outcome, whereas in reality, the relationship between 
MMSE at screening and the outcome parameters might have 
been more complex. We controlled for some patient character-
istics that have a well-known effect on brain oscillations, such 
as use of benzodiazepines and structural brain lesions, including 
infarctions and tumors. However, other, unknown, factors, such 
as brain atrophy or small vessel disease, might have biased the 
results. It, therefore, remains unclear to what extent the interven-
tion effect was masked by group differences already present at 
screening.
cOnclUsiOn
Possibly due to methodological issues (unbalanced and small 
study groups), we were not able to assess the potential of 
MEG-based measures as markers of an intervention effect of a 
medical food in mild AD patients. Furthermore, we could not 
replicate the EEG results from the well-powered Souvenir II study 
(n =  259) in which a significant effect of Souvenaid compared 
with control product was shown on peak frequency, functional 
connectivity, and brain network organization in patients with 
mild AD (14, 32). We did not demonstrate consistent statistically 
significant differences between groups for additional regional-
specific MEG outcome measures nor did we observe the typical 
AD deterioration over time in the control group. Substantially 
increasing the sample size for better-balanced study groups might 
give indications in this direction.
Magnetoencephalography did not seem less sensitive than 
EEG but with a greater ability of in-depth regional analysis. The 
potential of MEG analysis might be demonstrated in future, larger, 
clinical studies when the field has progressed toward a more 
unified data format. Moreover, newly developed MEG analyses 
with hippocampal and centroid voxel MEG virtual electrodes as 
well as other (directed) connectivity and network analysis can 
be applied to further characterize brain magnetic activity in AD.
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